Think Outside the Box With Intravenous Iron-The New Ferric Carboxymaltose FDA Boxed Warning.

The FDA’s new boxed warning for intravenous ferric carboxymaltose highlights potential dangers, but the warning may not fully explain the risks.

• Why it matters: Clinicians need clearer guidance on risks versus benefits, because the boxed warning is presented as insufficient for understanding potential harms.
• What they did: This Viewpoint reviews the FDA boxed warning for intravenous ferric carboxymaltose and discusses how it frames safety concerns and clinical use.
• The result: The discussion implies that current labeling may leave gaps in communicating danger, informing more cautious interpretation of risks and benefits.

AI summary of the abstract · may contain errors · not medical advice · read the paper.